Injection-site reactions are among the most commonly reported side effects: patients may experience pain, stinging, or mild burning at the IM injection site
By binding to Beclin-1, cGAS outcompetes run domain Beclin-1 interacting and cysteine-rich containing protein (Rubicon) (150)
Don't rush this part
Treatment recommendations, prescriptions, and follow-up care are based on your individual medical history, provider assessment, and clinical appropriateness
Not intended to diagnose, treat, cure, or prevent any condition.
Heres the reality: While animal studies show promise, large-scale human clinical trials for cosmetic skin rejuvenation are limited